3+ day, 12+ hour ago  (528+ words) Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consist. .. Bio NTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting - Pumitamig data from…...

1+ week, 5+ day ago  (367+ words) Company Remains on Track For Design Freeze by End of Year 2026 WALTHAM, Mass. , May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company), today announced the successful completion of…...

4+ day, 12+ hour ago  (18+ words) /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused. .....

2+ week, 5+ day ago  (544+ words) Generated $58. 6 million in revenue from resilient royalties portfolio Achieved IST U. S. net product sales of $34. 2 million for the first quarter, representing 29% year-over-year growth "We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress…...

1+ week, 5+ day ago  (191+ words) Evaxion Biotech ( (EVAX) ) has shared an update. The most recent analyst rating on (EVAX) stock is a Buy with a $16. 00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page....

2+ week, 10+ hour ago  (497+ words) CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance. Oops, something went wrong CSL Plunges 22% After Cutting Outlook And Flagging $5 Billion Impairments This article first appeared on Guru Focus. CSL Ltd....

1+ week, 6+ day ago  (402+ words) Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies advanced materially through late-stage regulatory and commercialization preparation as OST-HER2 moved from Phase 2bsupported planning…...

2+ week, 2+ day ago  (1056+ words) May 7, 2026 There was also a 50% reduction in the number of patient deaths and a 13. 3% reduction in recurrent strokes compared to placebo. These data inform the design and powering assumptions for the ongoing Re MEDy2 trial. I think you can understand why…...

1+ week, 5+ day ago  (454+ words) Focus on Advanced Sports Health and Digital Care Proceeds from any funds raised through the private equity facilitation are designated exclusively for MNDR's healthcare technology initiatives. These include the development and delivery of sports health physiotherapy and treatment programs, as…...

1+ week, 4+ day ago  (112+ words) Mobile-health Network Solutions Class A ( (MNDR) ) just unveiled an announcement. Spark's Take on MNDR Stock According to Spark, Tip Ranks' AI Analyst, MNDR is a Neutral. The score is held down primarily by weak financial performance (persistent losses, negative gross…...